Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pangaea OncologyXMAD:PANG -4.46%60 Days Inventory is 248.09 as of Dec. 2025, which is 64% below its 10-year median of 681.20. GuruFocus rates XMAD:PANG with a GF Score™ of 60/100 and a GF Value™ of €2.17 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Pangaea Oncology ranks worse than 98.88% on this metric.
The historical rank and industry rank for Pangaea Oncology's Days Inventory or its related term are showing as below:
XMAD:PANG'
s Days Inventory Range Over the Past 10 Years
Min: 453.4 Med: 681.2 Max: 908.99
Current: 825.93
During the past 13 years, Pangaea Oncology's highest Days Inventory was 908.99. The lowest was 453.40. And the median was 681.20.
XMAD:PANG's Days Inventory is ranked worse than 98.88% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs XMAD:PANG: 825.93
Pangaea Oncology's Days Inventory
declined
from Dec. 2024 (1,113.56) to Dec. 2025 (248.09).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pangaea Oncology's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.74.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pangaea Oncology's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.03.
Pangaea Oncology (XMAD:PANG) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Pangaea Oncology's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pangaea Oncology's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Pangaea Oncology Days Inventory Related Terms
Pangaea Oncology Days Inventory Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Days Inventory distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a Days Inventory of 248.09 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pangaea Oncology and its competitors. This is 64% below median its historical median of 681.20. Over the past decade, Pangaea Oncology's Days Inventory has ranged from 453.40 to 908.99. According to the industry distribution chart, Pangaea Oncology ranks #177 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 98.9%.
Is Pangaea Oncology's Days Inventory too high?
Pangaea Oncology's current Days Inventory of 248.09 is 64% below median its 10-year median of 681.20. Over the past 10 years, this metric has ranged from a low of 453.40 to a high of 908.99. The Medical Diagnostics & Research industry median Days Inventory is 65.04. Pangaea Oncology's value of 248.09 is 281.4% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #177 out of 179 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Pangaea Oncology has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #177 out of 179 companies for Days Inventory. This places Pangaea Oncology in the lower half of its industry. The industry median Days Inventory is 65.04. Pangaea Oncology's value of 248.09 is 281.4% above this benchmark. Historically, Pangaea Oncology's own Days Inventory has ranged from 453.40 to 908.99 over the past decade. While the company's 10-year median is 681.20 vs. the industry median of 65.04, Pangaea Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current Days Inventory of 248.09 is 281.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Days Inventory is 248.09, which is 64% below median its own 10-year median of 681.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.17, compared to a current price of €1.50 — trading 30.9% below its estimated fair value. The current Days Inventory is 248.09, which is 64% below median its 10-year median of 681.20 and 281.4% above the Medical Diagnostics & Research industry median of 65.04. Pangaea Oncology's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Days Inventory is 248.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.50 is trading 30.9% below its estimated GF Value™ of €2.17.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Days Inventory: 248.09 (64% below median its 10-year median of 681.20)
GF Value™: €2.17 vs. price of €1.50 (30.9% below fair value)
Industry Position: 281.4% above the Medical Diagnostics & Research median (#177 of 179)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
60GF Score
Get the complete analysis for XMAD:PANG
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
